Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result
<strong>Background:</strong> Blood biomarkers may aid in recruitment to clinical trials of Alzheimer’s disease (AD) modifying therapeutics by triaging potential trials participants for amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ and tau tests. <strong&g...
المؤلفون الرئيسيون: | Westwood, S, Baird, AL, Hye, A, Ashton, NJ, Nevado-Holgado, AJ, Anand, SN, Liu, B, Newby, D, Bazenet, C, Kiddle, SJ, Ward, M, Newton, B, Desai, K, Hehir, C, Zanette, M, Galimberti, D, Parnetti, L, Lleó, A, Baker, S, Narayan, VA, Van Der Flier, WM, Scheltens, P, Teunissen, CE, Visser, PJ, Lovestone, S |
---|---|
التنسيق: | Journal article |
منشور في: |
Frontiers Media
2018
|
مواد مشابهة
-
Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result
حسب: Sarah Westwood, وآخرون
منشور في: (2018-12-01) -
The influence of insulin resistance on CSF and plasma biomarkers of Alzheimer’s pathology
حسب: Westwood, S, وآخرون
منشور في: (2017) -
New CSF biomarkers on the block
حسب: Charlotte E Teunissen, وآخرون
منشور في: (2016-09-01) -
Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
حسب: Rosha Babapour Mofrad, وآخرون
منشور في: (2019-12-01) -
Determining the molecular pathways underlying the protective effect of non-steroidal anti-inflammatory drugs for Alzheimer's disease: A bioinformatics approach
حسب: Nevado-Holgado, A, وآخرون
منشور في: (2016)